335,493 Shares in Stevanato Group S.p.A. $STVN Acquired by Confluence Investment Management LLC

Confluence Investment Management LLC acquired a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 335,493 shares of the company’s stock, valued at approximately $6,062,000.

Other hedge funds also recently bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of Stevanato Group by 10.8% during the first quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock worth $8,930,000 after purchasing an additional 42,731 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Stevanato Group by 16.9% during the second quarter. Sei Investments Co. now owns 231,244 shares of the company’s stock valued at $5,649,000 after purchasing an additional 33,419 shares during the period. Raymond James Financial Inc. grew its holdings in shares of Stevanato Group by 21.2% in the second quarter. Raymond James Financial Inc. now owns 567,803 shares of the company’s stock worth $13,871,000 after purchasing an additional 99,328 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Stevanato Group by 14.2% in the second quarter. Ameriprise Financial Inc. now owns 708,821 shares of the company’s stock worth $17,316,000 after purchasing an additional 87,942 shares during the last quarter. Finally, Bamco Inc. NY increased its stake in Stevanato Group by 2.1% in the 2nd quarter. Bamco Inc. NY now owns 1,888,050 shares of the company’s stock worth $46,125,000 after buying an additional 39,528 shares during the period.

Stevanato Group Price Performance

Shares of STVN stock opened at €19.78 on Wednesday. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The stock has a market capitalization of $5.99 billion, a price-to-earnings ratio of 33.52, a P/E/G ratio of 1.84 and a beta of 0.77. The stock has a fifty day simple moving average of €18.70 and a two-hundred day simple moving average of €16.97. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.21.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The firm had revenue of €273.57 million for the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 earnings per share. On average, analysts predict that Stevanato Group S.p.A. will post 0.71 EPS for the current fiscal year.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Stevanato reported second-quarter revenue of €302.0 million, an 8% year-over-year increase. High-value solutions accounted for 45% of revenue, and gross profit margin improved, indicating continued demand for the company’s drug-containment, drug-delivery and diagnostic products. Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
• Positive Sentiment: Management raised or reaffirmed a favorable 2026 outlook, calling for EPS of $0.700-$0.720 versus analyst expectations of $0.680. Revenue guidance was approximately $1.5 billion, broadly in line with consensus, suggesting profitability is expected to outperform despite modest top-line expectations.
• Positive Sentiment: The company is targeting €335 million to €345.2 million in adjusted EBITDA for 2026 following the divestiture of Balda C. Brewer. The target gives investors a clearer view of expected profitability after the portfolio change. Stevanato targets adjusted EBITDA following Balda C. Brewer divestiture
• Neutral Sentiment: The earnings-call coverage focused on the company’s second-quarter performance, updated guidance and strategy following the divestiture. Investors are likely looking for further detail on demand trends, margins and the pace of growth during the call. Stevanato Group Q2 2026 Earnings Call Transcript
• Negative Sentiment: Reported quarterly EPS was mixed: one report cited €0.14 versus a €0.15 consensus estimate, while another cited $0.16 versus a $0.15 estimate. The conflicting figures may be creating uncertainty, but the reported miss in the company’s local-currency presentation could be weighing on the stock despite the stronger guidance.

Insider Buying and Selling at Stevanato Group

In other Stevanato Group news, Director Donald E. Morel, Jr. sold 1,493 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of €17.09, for a total transaction of €25,515.37. Following the transaction, the director owned 37,424 shares of the company’s stock, valued at approximately €639,576.16. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William J. Federici sold 1,493 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of €17.09, for a total transaction of €25,515.37. Following the transaction, the director directly owned 26,991 shares in the company, valued at €461,276.19. This trade represents a 5.24% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,972 shares of company stock valued at $102,061 in the last ninety days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on STVN shares. Weiss Ratings upgraded shares of Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 16th. TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a research note on Wednesday, June 17th. Finally, Wolfe Research assumed coverage on shares of Stevanato Group in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Stevanato Group Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.